tenofovir disoproxil sold trade name viread among others medication used treat chronic hepatitis b prevent treat generally recommended use may used prevention hivaids among high risk exposure needlestick injury potential sold together combinations emtricitabinetenofovir cure hivaids hepatitis available mouth tablet common side effects include nausea rash diarrhea headache pain depression severe side effects include high blood lactate enlarged absolute often recommended pregnancy appears nucleotide reverse transcriptase inhibitor works decreasing ability viruses tenofovir patented approved use united states world health organizations list essential available united states generic medication tenofovir disoproxil used infection chronic hepatitis b treatment infection tenofovir indicated combination antiretroviral agents people years age older chronic hepatitis b patients tenofovir indicated patients years age tenofovir used hiv prevention people high risk infection sexual transmission injecting drug use cochrane review examined use tenofovir prevention hiv exposure found tenofovir alone tenofoviremtricitabine combination decreased risk contracting hiv high risk us centers disease control prevention cdc also conducted study partnership thailand ministry public health ascertain effectiveness providing people inject drugs illicitly daily doses tenofovir prevention measure results revealed reduced incidence virus among group subjects received drug comparison control group received tenofovir disoproxil generally well tolerated low discontinuation rates among hiv chronic hepatitis b contraindications use commonly reported side effects due use tenofovir disoproxil dizziness nausea adverse effects include depression sleep disturbances headache itching rash fever us boxed warning cautions potential onset lactic acidosis liver damage due use tenofovir long term use tenofovir disoproxil associated nephrotoxicity bone loss presentation nephrotoxicity appear fanconi syndrome acute kidney injury decline glomerular filtration rate discontinuation tenofovir disoproxil potentially lead reversal renal impairment nephrotoxicity may due proximal tubules accumulation tenofovir disoproxil leading elevated serum tenofovir interacts didanosine protease inhibitors tenofovir increases didanosine concentrations result adverse effects pancreatitis neuropathy tenofovir also interacts protease inhibitors atazanavir decreasing atazanavir concentrations increasing tenofovir addition since tenofovir excreted kidney medications impair renal function also cause tenofovir disoproxil nucleotide analog reversetranscriptase inhibitor selectively inhibits viral reverse transcriptase crucial enzyme retroviruses human immunodeficiency virus hiv showing limited inhibition human enzymes dna polymerases α β mitochondrial dna polymerase vivo tenofovir disoproxil fumarate converted tenofovir acyclic analog deoxyadenosine damp tenofovir lacks hydroxyl group position corresponding carbon damp preventing formation phosphodiester linkage essential dna chain incorporated growing dna strand tenofovir causes premature termination dna transcription preventing viral tenofovir disoproxil prodrug quickly absorbed gut cleaved release inside cells tenofovir phosphorylated tenofovir diphosphate analogous triphosphate tenofovir already one phosphonate residue active compound inhibits reverse transcriptase via chain fasting persons bioavailability highest blood plasma concentrations reached one taken fatty food highest plasma concentrations reached two hours area curve increased inhibitor cytochrome tenofovir mainly excreted via kidneys glomerular filtration tubular secretion using transport proteins tenofovir may measured plasma liquid chromatography testing useful monitoring therapy prevent drug accumulation toxicity people kidney liver tenofovir derivative adenine chemical starting point first published included patents drug development attention switched phosphonate ester derivative tenofovir disoproxil subject extensive process chemistry provide viable manufacturing route adenine first reacted chiral version propylene carbonate r absolute configuration using sodium hydroxide base conditions reaction regioselective alkylation occurring exclusively imidazole ring lesshindered carbon dioxolane second step hydroxyl group reacted phosphonic acid derivative using tertbutyllithium base ensure selective oalkylation formation ether bond tenofovir formed diethyl phosphonate group converted acid using trimethylsilyl chloride presence sodium bromide refinement original manufacturing synthesis alternative ester tenofovir disoproxil completed alkylation appropriate chloromethyl ether derivative may purified fumarate tenofovir initially synthesized antonín holý institute organic chemistry biochemistry czechoslovak academy sciences prague patent filed makes mention potential use compound treatment hiv infection claims activity herpes simplex de clercq holý described activity pmpa hiv cell shortly thereafter collaboration biotechnology company gilead sciences led investigation pmpas potential treatment hiv infected patients researchers gilead university california san francisco demonstrated tenofovir exhibits antihiv effects humans dosed subcutaneous initial form tenofovir used studies limited potential widespread use poorly penetrated cells absorbed given mouth gilead developed prodrug version tenofovir tenofovir disoproxil version tenofovir often referred simply tenofovir version drug two negative charges tenofovir phosphonic acid group masked thus enhancing oral absorption tenofovir disoproxil approved us treatment hiv treatment chronic hepatitis tenofovir disoproxil taken mouth sold brand name viread among tenofovir disoproxil prodrug form tenofovir phosphonate liberated intracellularly converted tenofovir marketed gilead sciences fumarate abbreviated tenofovir disoproxil also available pills combine number antiviral drugs single dose wellknown combinations include atripla tenofovir disoproxilemtricitabineefavirenz complera tenofovir disoproxilemtricitabinerilpivirine stribild tenofovir disoproxilemtricitabineelvitegravircobicistat truvada tenofovir gilead created second prodrug form active drug tenofovir diphosphate called tenofovir alafenamide differs tenofovir disoproxil due activation lymphoid cells allows active metabolites accumulate cells leading lower systemic exposure potential httpsenwikipediaorgwikitenofovirdisoproxil